Piper Sandler Companies

Rivian stock declined 11.2% this week following two analyst downgrades. Wolfe Research downgraded the stock to underperform with a $16 price target, citing continued EBITDA losses and concerns about reduced EV demand. UBS also downgraded to sell with a $15 price target. However, not all analysts are bearish—Piper Sandler raised its price target...

Tesla faces its upcoming earnings report with significant tension as the stock navigates conflicting analyst outlooks. While bears cite declining production, intensifying competition, and an extremely high P/E ratio of 300 as warning signs, bulls argue the market underestimates Tesla's diversification into robotics, energy, and autonomous driving...

Protara Therapeutics plans to raise approximately $75 million through a public offering of 13,043,479 common stock shares at $5.75 per share, with proceeds intended to fund clinical development of TARA-002 and other programs.

Protara Therapeutics plans to raise $75 million through a public offering of common stock and pre-funded warrants. The proceeds will fund clinical development of TARA-002 and other clinical programs, with J.P. Morgan, TD Cowen, and Piper Sandler acting as joint book-running managers.

Kestra Medical Technologies is conducting a public offering of 6,000,000 common shares at $23.00 per share, expecting to raise $138 million. The offering includes an option for underwriters to purchase an additional 900,000 shares.